Table 2 Tumour characteristics of breast cancers with or without a diagnostic delay following recall in cohort 2.
Delay in breast cancer diagnosis (N = 98)a | No delay in breast cancer diagnosis (N = 3413) | P value | |
|---|---|---|---|
Type of cancer, N (%) | 0.005 | ||
DCIS | 9 (9.2) | 710 (20.8) | |
Invasive | 89 (90.8) | 2703 (79.2) | |
Histology of invasive cancers, N (%) | |||
Ductal | 64 (71.9) | 2137 (79.0) | 0.006 |
Lobular | 11 (12.4) | 322 (11.9) | |
Ductolobular | 1 (1.1) | 101 (3.7) | |
Other | 13 (14.6) | 143 (5.3) | |
Tumour stage of invasive cancers, N (%) | |||
T1a + b | 32 (35.9) | 945 (35.0) | 0.32 |
T1c | 40 (44.9) | 1196 (44.2) | |
T2+ | 17 (19.2) | 558 (20.6) | |
Unknown | 0 | 4 (0.1) | |
Lymph node status of invasive cancers, N (%) | |||
N+ | 13 (14.6) | 614 (22.7) | 0.14 |
N− | 75 (84.3) | 2023 (74.9) | |
Unknown | 1 (1.1) | 66 (2.4) | |
Bloom & Richardson grade, N (%) | |||
I | 38 (42.7) | 1213 (44.9) | 0.19 |
II | 39 (43.8) | 1145 (42.4) | |
III | 11 (12.4) | 308 (11.4) | |
Unknown | 1 (1.1) | 37 (1.4) | |
Oestrogen receptor status, N (%) | |||
Positive | 82 (92.1) | 2429 (89.9) | 0.80 |
Negative | 7 (7.9) | 259 (9.6) | |
Unknown | 0 | 15 (0.6) | |
Progesterone receptor status, N (%) | |||
Positive | 57 (64.0) | 1 943 (71.9) | 0.16 |
Negative | 32 (36.0) | 737 (27.3) | |
Unknown | 0 | 23 (0.9) | |
Her2/Neu receptor status, N (%) | |||
Positive | 6 (6.7) | 262 (9.7) | 0.81 |
Negative | 83 (93.3) | 2415 (89.3) | |
Unknown | 0 | 26 (1.0) | |
Triple-negative receptor status, N (%) | |||
Yes | 5 (5.6) | 173 (6.4) | 0.99 |
No | 84 (94.4) | 2515 (93.0) | |
Unknown | 0 | 15 (0.6) | |
Final surgical treatment, N (%) | |||
Breast conserving surgery | 78 (79.5) | 2756 (80.8) | 0.74 |
Mastectomy | 18 (18.4) | 616 (18.0) | |
No surgery | 2 (2.1) | 41 (1.2) | |
